NHS launches puberty blocker trial for young people under 16

A £10 million trial for puberty blockers for trans youth will proceed, despite previous bans and criticism. Health Secretary Wes Streeting stated the trial prioritizes scientific evidence and child safety. The trial, named Pathway, will assess the benefits and risks of puberty blockers for up to 226 young people under 16. It follows recommendations from the Cass Review and requires parental consent and rigorous assessment. This trial represents the only current NHS access to puberty blockers for this age group. Critics argue decades of evidence support their safety, while the ban causes psychological harm.